Participant flow

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas · Source last updated 2020-01-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Abraxane 220 mg/m\^2 intravenously on Day 1 of 21 day cycle.

   id

   FG000

   title

   Abraxane

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Progressive Disease

   2. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Inadequate Trial

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Hospice

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         13

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Recruitment Period: November 2012 to October 2015. All recruitment done at The University of Texas MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice